This therefore produces new biological properties in the resulting analogs, such as better fitting into HLA-DRβ1* molecules as shown, and hence induces a protective immune response against malaria, providing new clues in developing a site-directed, modified sub-unit-based, multi-component, synthetic malaria vaccine. The gene discussed is HLA-DRB1; the disease is malaria.